ERBB2 and neoplasm: As shown in Figure 4, prediction in the HR+/HER2-, HER2+, triple-negative, and tumor sized ≤ 3cm and tumor sized>3 cm subgroups achieved discrimination performance in the whole group, yielding an AUC of 0.937 (95%CI, 0.879-0.995), 0.918 (95%CI, 0.855-0.982), 0.885 (95%CI, 0.655-0.999), 0.930 (95%CI, 0.876-0.985) and 0.913 (95%CI, 0.840-0.986) respectively.